Actinium Pharmaceuticals (NYSE:ATNM) Trading 1.9% Higher – Here’s Why

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) was up 1.9% on Tuesday . The stock traded as high as $0.9201 and last traded at $0.90. Approximately 50,584 shares were traded during mid-day trading, a decline of 65% from the average daily volume of 145,028 shares. The stock had previously closed at $0.8830.

Wall Street Analyst Weigh In

Separately, Stephens reissued an “overweight” rating and set a $5.00 price target on shares of Actinium Pharmaceuticals in a report on Tuesday, March 31st. One analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $5.00.

Actinium Pharmaceuticals Trading Up 1.9%

The firm’s 50-day simple moving average is $1.05 and its 200 day simple moving average is $1.15. The stock has a market cap of $28.24 million, a P/E ratio of -0.65 and a beta of -0.02.

Institutional Trading of Actinium Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in ATNM. Vanguard Group Inc. grew its stake in shares of Actinium Pharmaceuticals by 0.9% in the third quarter. Vanguard Group Inc. now owns 1,384,543 shares of the company’s stock worth $2,215,000 after purchasing an additional 12,703 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Actinium Pharmaceuticals by 20.7% during the first quarter. Renaissance Technologies LLC now owns 471,600 shares of the company’s stock valued at $469,000 after purchasing an additional 80,816 shares during the period. Two Sigma Investments LP increased its holdings in shares of Actinium Pharmaceuticals by 403.4% during the third quarter. Two Sigma Investments LP now owns 234,293 shares of the company’s stock valued at $375,000 after purchasing an additional 187,748 shares during the period. Jane Street Group LLC bought a new stake in shares of Actinium Pharmaceuticals during the second quarter valued at about $306,000. Finally, Marshall Wace LLP bought a new stake in shares of Actinium Pharmaceuticals during the second quarter valued at about $137,000. Institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.